COVID-19 vaccination in Chad
| Date | June 4, 2021 |
|---|---|
| Cause | COVID-19 pandemic |
COVID-19 vaccination in Chad is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Chad began its vaccination program on 4 June 2021, initially after receiving 200,000 doses of the Sinopharm BIBP vaccine donated by China.[1] As of 10 June 2021, 5,324 doses have been administered.[2]
History
Timeline
June 2021
Vaccinations started on 4 June, initially with 200,000 doses of the Sinopharm BIBP vaccine donated by China. By the end of the month 11,390 doses had been administered.[3]
July 2021
By the end of the month 26,511 doses had been administered.[3]
August 2021
By the end of the month 51,697 doses had been administered.[3]
September 2021
By the end of the month 130,369 doses had been administered.[3]
October 2021
By the end of the month 224,180 doses had been administered while 1% of the target population had been fully vaccinated.[3]
November 2021
By the end of the month 258,618 doses had been administered while 1% of the target population had been fully vaccinated.[3]
December 2021
By the end of the month 330,522 doses had been administered while 1% of the target population had been fully vaccinated.[3]
January 2022
By the end of the month 374,952 doses had been administered while 2% of the target population had been fully vaccinated.[3]
Progress
Cumulative vaccinations in Chad[4]
References
- ↑ Bazzara-Kibangula, Aurélie (6 June 2021). "Le Tchad lance sa campagne de vaccination contre le Covid-19" (in French). RFI. Retrieved 11 June 2021.
- ↑ "owid/covid-19-data". GitHub. Retrieved 19 June 2021.
- 1 2 3 4 5 6 7 8 Africa COVID-19 dashboard (World Health Organization).
- ↑ "owid/covid-19-data". GitHub. Retrieved 7 March 2021.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
.svg.png.webp){kind=small}
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.